4D printing has attracted tremendous interest because of its potential applications in smart devices, biomedical and tissue engineering. However, conventional shape memory polymers suffer from the single permanent shape and recovery direction, the flexibility of 4D printing is significantly limited. Besides, the cross‐linked networks of photocuring 3D‐printed objects cannot be reprocessed or repaired. To address these issues, the dynamic thiocarbamate bonds are introduced into the photocurable methacrylate to prepare reprocessable and self‐healable 4D printing polythiourethane (4DP‐PTU) with Young's modulus of 1.2 GPa and tensile strength of 61.9 MPa. The printed objects can be easily repaired by reprinting on the damaged surface. The shape memorized 4DP‐PTU features high shape fixity and shape recovery, and reconfigurable permanent shape brought by the solid‐state plasticity. A dual‐mode triggered alarm is obtained by the incorporation of carbon nanotubes to demonstrate the potential application in smart alarms for warning of laser exposure or fire case. Moreover, the surface wettability and cell adhesion performance of 4DP‐PTU with excellent biocompatibility can be facilely adjusted through the exchange reaction with sulfhydryl compounds. Accordingly, 4DP‐PTU may show vast potential applications in the field of robotics, smart alarm, bio‐implants and in solving the environmental challenges of 3D‐printed products.

No abstract

Background China implemented the national drug price negotiation (NDPN) policy to include 17 innovative anticancer medicines in the national reimbursement drug list in 2018. We aimed to assess the impact of this policy on the utilization, cost, and accessibility of anticancer medicines. MethodsWe obtained monthly medicine procurement data from 1039 hospitals from October 2017 to December 2019. We examined changes in availability, utilization, defined daily dose cost (DDDc), and affordability of the medicines using descriptive statistics and controlled interrupted time series analysis, measuring utilization by defined daily doses (DDDs). Cetuximab and raltitrexed were compared separately for the same indication. ResultsThe mean availability of 17 negotiated anticancer medicines was 28.78% after the NDPN, amounting to an increase of 25.22%. The availability increased by 7.88% (95% confidence interval (CI) = 4.31%, 11.45%, P < 0.001) immediately and by 1.23% (95% CI = 0.81%, 1.64%, P < 0.001) per month after policy implementation. Compared with the control group, the utilization of the medicines increased by 11.44 DDDs (95% CI = 2.42, 20.46, P = 0.014) immediately and by 3.54 DDDs (95% CI = 2.47, 4.60, P < 0.001) per month after policy implementation, while the DDDc decreased by US$109.09 (95% CI = 68.14, 150.05, P < 0.001) immediately and remained stable thereafter. The results on cetuximab and raltitrexed were similar. Availability and utilization differed among regions in east, middle, and west China. Out-of-pocket costs decreased by 17.35 times the catastrophic health expenditures to 1.99 times, but the affordability ratio for 14 negotiated medicines was still greater than 1. ConclusionsThe NDPN policy improved the availability, utilization, and affordability of anticancer medicines. China's experience in NDPN provides a reference for other countries. However, the availability and affordability of anticancer medicines still need further improvement.Cancer has become a leading cause of death globally, accounting for nearly 10 million deaths, or nearly one in six deaths in 2020 [1]. Among them, lung cancer was the most common cause of cancer death, accounting for 1.80 million. In China, there were 4.57 million new cancer cases, accounting for 23.7% of the cases globally, and three million cancer deaths, accounting for 30% of cancer deaths globally in 2020 [2]. China ranked first in the world in both the number of new cancer cases and cancer deaths, far surpassing other countries in the world. Cancer has become a major problem affecting human health. Simultaneously, cancer treatment expenditures appear to be catastrophic for patients in China [3]. About half of cancer patients borrowed money or went into debt and approximately 10% of cancer patients reported forgoing some medical care because of cost [4]. Many cancer patients cannot afford targeted anticancer medicines -the main cancer treatment [5].

The Internet of medical things is an emerging information network technology, which can realize the automatic identification, monitoring and management of personnel, medical equipment, medicines, etc. through this network, and is an effective means to reduce medical errors and improve work efficiency. This article first studies the theory and method of health information and sports information collection, that is, the temperature sensor and the acceleration sensor are used to collect human body temperature and exercise steps, respectively, and then estimate the human health and sports. Second, the prototype system of health and sports information collection system is realized the system is divided into two parts: terminal node and client information management system. Finally, a component collaborative modeling and data analysis method for Internet of medical things is proposed. This method constructs different types of components according to different functions of the Internet of Things equipment, and designs a set of communication mechanisms between the components based on the Internet of Things network communication characteristics, and uses visual methods to model. The experimental results verify that the method of collecting and analyzing human motion information using a motion information collection system is feasible. Multiple methods should be integrated to obtain as much information as possible to make the human motion analysis more scientific and reasonable.INDEX TERMS Internet of medical things, motion information collection, collaborative modeling, data analysis, prototype.

Purpose This study aimed to evaluate Atorvastatin (ATO)-associated hepatotoxicity using prescription sequence symmetry analysis (PSSA), based on a health insurance database of a Chinese population living in Jiangsu Province, China. Methods Patients prescribed ATO and hepatoprotective drugs in 2017 were identified, and the run-in period was determined based on the “waiting-time” distribution. Adjusted sequence ratio (ASR) and 95% confidence interval (95% CI) were calculated to estimate the risk of ATO-associated hepatotoxicity under different time intervals or based on gender and age stratification. Results A total of 2,549 patients, with 1,518 filling the ATO prescription first and 1,031 filling the ATO prescription second, were analyzed. After setting the run-in period as 30 days and the time interval as 15, 30, 60, 90, 120, and 180 days, the ASRs were 1.492 (95% CI: 1.367–1.652), 1.399 (95% CI: 1.308–1.508), 1.280 (95% CI: 1.213–1.357), 1.292 (95% CI: 1.234–1.356), 1.278 (95% CI: 1.226–1.336), and 1.274 (95% CI: 1.229–1.323), respectively. No significant difference was observed between different genders and ages (χ 2 =0.161, P =0.688; χ 2 =1.565, P =0.211, respectively). Conclusion This is the first study conducted in a real-world setting to evaluate the relationship between ATO and hepatotoxicity using the PSSA in a Chinese population. We found a 1.3- to 1.5-fold increase in risk of hepatotoxicity following ATO, with the greater risk occurring within the first 30 days of treatment.